Antihypertensive medications and risk of Alzheimer's disease: Evidence for specific medication use

Read full text Summarise with VIRAT
Authors: Osvaldo Laurido-Soto, Alejandra Camacho‐Soto, Irene M. Faust, Kassu Mehari Beyene, Aaron Jacob Katz, Jordan A. Killion, Brad Alan Racette
Cited by: 0
References: 43

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract BACKGROUND Hypertension is a modifiable risk factor for Alzheimer's disease (AD). Specific antihypertensive classes may lower/increase AD risk by affecting the renin–angiotensin–aldosterone system. METHODS We investigated AD risk in relation to antihypertensive medications in a population‐based study of 33,714 incident AD cases and 897,872 controls from Medicare data. Multinomial logistic regression models were adjusted for age, sex, race/ethnicity, smoking probability, and health‐care use. We performed 3‐year exposure lagged, 90‐day continuous medication prescription, and proportion of days covered analyses. RESULTS Beneficiaries prescribed angiotensin receptor blockers (ARBs; odds ratios [ORs] 0.93, 95% confidence intervals [CIs] 0.91–0.95) or thiazides (OR 0.93, 95% CI 0.91–0.95) had an inverse association of developing incident AD, while beneficiaries taking angiotensin converting enzyme inhibitors (OR 1.08, 95% CI 1.06–1.11) had a positive association with developing incident AD. DISCUSSION ARB medications and thiazide diuretics may be the preferred antihypertensive in patients at risk of AD.

Fields of Study & Subjects

Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Blood Pressure and Hypertension Studies

Publication details

Journal / source
Alzheimer s & Dementia Translational Research & Clinical Interventions
Volume
12
Issue
2
Publication date
26 March 2026
Language
EN